Captagon® was once a medicine containing fenethylline. Tablets sold illicitly under that name today usually contain amphetamine and may contain caffeine or other substances, so their contents, strength and effects are unpredictable.
This resource explains the difference between the historical medicine and the current illicit market, the possible stimulant harms, warning signs that require emergency help, and evidence-based support for stimulant use disorder.
Captagon® was a brand name for a medicine containing fenethylline, a stimulant introduced in the 1960s and later withdrawn from legitimate medical use. Fenethylline is metabolised to amphetamine and theophylline, but the historical medicine should not be treated as equivalent to tablets sold illicitly under the Captagon name today.
Forensic and European drug-market reports indicate that current illicit “captagon” tablets usually contain amphetamine, often with caffeine and sometimes other substances. Contents and strength vary, and a familiar color, stamp or two-crescent logo does not verify what a tablet contains.
How Stimulant Effects Arise
Amphetamine increases signaling involving dopamine and noradrenaline. This can increase alertness and energy, but it can also raise heart rate, blood pressure and body temperature and cause agitation, anxiety or psychosis. Effects cannot be predicted reliably when the ingredients and dose are unknown.
Illicit Captagon is not an approved treatment for ADHD, narcolepsy, depression or fatigue. People with those conditions should use treatments assessed and prescribed for them by a qualified clinician.
The illicit market for tablets sold as captagon is concentrated in parts of the Near and Middle East, while European countries can be involved in production or trans-shipment. Seizure figures describe law-enforcement activity and supply; they do not measure how many people use the drug or how many have a stimulant use disorder.
People may use stimulants for wakefulness, energy, work, study or recreation, but no single social group or motive defines use. Claims that captagon is routinely issued to fighters or directly causes violence should not be presented as established facts without toxicological and case-specific evidence.
Because the tablets are clandestinely manufactured, changes in trafficking routes, stamps or price do not provide reliable information about purity or health risk.
Possible short-term stimulant effects include wakefulness, increased energy, reduced appetite, sweating, dry mouth, dilated pupils and a faster heart rate. Some people experience euphoria or greater confidence; others experience anxiety, panic, agitation, confusion or paranoia.
Serious toxicity can include very high blood pressure, abnormal heart rhythm, chest pain, overheating, seizures, stroke, psychosis, collapse or death. Combining an unknown stimulant tablet with other stimulants, some antidepressants, alcohol or other drugs can add risks and make the clinical picture harder to predict.
Repeated use may be associated with sleep disturbance, weight loss, low mood, cognitive difficulties and stimulant use disorder. Symptoms vary and cannot be assigned to fenethylline when the tablet’s actual ingredients are unknown.
There is no reliable onset, peak or duration for an illicit tablet sold as Captagon. Timing depends on the ingredients, dose, route, other substances, health conditions and individual metabolism. A logo or claimed strength cannot establish when a tablet will take effect or when it has cleared.
Stimulant effects and impaired judgment may continue after the most noticeable euphoria or energy has faded. A later “crash” can involve fatigue, sleep changes, irritability, anxiety, low mood and cravings.
Do not use a fixed waiting period to decide that driving, taking another dose or mixing another substance is safe. New or worsening chest pain, severe overheating, seizure, collapse, severe confusion, hallucinations or breathing difficulty requires emergency help.
Fenethylline was placed under international control in Schedule II of the 1971 Convention on Psychotropic Substances in 1986. National laws apply to the substances actually present in an illicit tablet; there is no regulated, standardized modern Captagon product.
Medical History
The historical fenethylline medicine was used in some countries for conditions including narcolepsy and attention problems. It is no longer produced for legitimate therapeutic use. Illicit captagon tablets are not a substitute for prescribed ADHD or sleep-disorder treatment.
When To Get Emergency Help
Call 999 in the UK for chest pain, severe overheating, seizures, collapse, severe confusion, hallucinations with dangerous behavior, or breathing problems after a suspected stimulant. Tell emergency staff what may have been taken, when and whether other substances were involved. Do not wait for a tablet to “wear off” when serious symptoms are present.
Common And Serious Effects
- restlessness, anxiety, insomnia, reduced appetite, sweating, headache and dry mouth
- rapid heart rate, raised blood pressure, palpitations and chest pain
- agitation, panic, paranoia, hallucinations or stimulant-induced psychosis
- overheating, dehydration, abnormal heart rhythm, seizures, stroke or collapse
Risk is affected by dose, unknown ingredients, repeated dosing, sleep deprivation, dehydration, underlying heart or mental-health conditions and use with other substances. A tablet that looks like one previously taken may have different contents.
Dependence And Withdrawal
Stimulant use disorder is assessed from a pattern such as loss of control, craving, unsuccessful attempts to cut down and continued use despite harm. After repeated use, stopping can be followed by fatigue, disturbed sleep, low mood, increased appetite and cravings. Severe depression, suicidal thoughts or psychosis needs urgent clinical assessment.
The original fenethylline medicine and today’s illicit captagon tablets are different products. Current tablets usually contain amphetamine but have variable, unregulated contents, so their effects and toxicity are unpredictable.
Treatment should be based on individual needs. Evidence supports psychosocial approaches such as contingency management and cognitive behavioral therapy for stimulant use disorders; there is no universally established medication that reliably treats amphetamine dependence. Co-existing mental-health, sleep, cardiovascular and other substance-use problems should also be assessed.
Emergency symptoms require immediate help. Ongoing use, cravings or difficulty stopping can be discussed confidentially with a GP or specialist drug service; a return to use should prompt renewed support, not stigma or an assumption that treatment has failed.
